Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2623
Título : Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases.
Autor : Alcaide, Julia
Delgado, Mayte
Legerén, Marta
Jurado, José Miguel
Blancas, Isabel
Pereda, Teresa
López, Jorge
Garrido, Margarita
Sánchez, María J
García, José L
Rueda, Antonio
Filiación: [Alcaide,J; Rueda,A] Oncology Department, Costa del Sol Hospital, Marbella, Málaga, Spain. [Delgado,M; Legerén,M; Jurado,JM; Blancas,I; Sánchez,MJ; García,JL] Oncology Department, San Cecilio Clinical Hospital, Granada, Andalucía, Spain. [Pereda,T; López,J] Pathology Department, Costa del Sol Hospital, Marbella, Málaga, Spain. [Garrido,M] Pharmacy and Nutrition Department, Costa del Sol Hospital, Marbella, Málaga, Spain.
Palabras clave : Metastatic colorectal cancer
Aflibercept
Angiogenesis
Targeted therapy
VEGF
VEGFR
Camptotecina
Neoplasias colorrectales
Ensayos de Uso compasivo
Supervivencia sin enfermedad
Humanos
Hipertensión
Mutación
Compuestos organoplatinos
Poliésteres
Proteinuria
Proteínas recombinantes de fusión
Receptores de Factores de crecimiento endotelial vascular
MeSH: Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Alkaloids::Camptothecin
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Therapies, Investigational::Compassionate Use Trials
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation
Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia
Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Organometallic Compounds::Organoplatinum Compounds
Medical Subject Headings::Chemicals and Drugs::Macromolecular Substances::Polymers::Polyesters
Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Urological Manifestations::Proteinuria
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Recombinant Proteins::Recombinant Fusion Proteins
Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases::Receptor Protein-Tyrosine Kinases::Receptors, Vascular Endothelial Growth Factor
Fecha de publicación : Nov-2016
Editorial : Spandidos Publications
Cita Bibliográfica: Alcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, et al. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncol Lett. 2016 ; 12(5):3127-3134
Abstract: Aflibercept is a recombinant fusion protein that acts by inhibiting tumoural angiogenesis. Efficacy data obtained in the VELOUR randomised study has contributed to the approval of aflibercept as a second-line metastatic colorectal cancer (mCRC) treatment following an oxaliplatin-based regimen. The present study reports a case series of five patients with mCRC, who were treated in two centres since 2011 in the Compassionate Use Program for aflibercept. All patients had a KRAS mutation and previously received palliative fluoropyrimidine-oxaliplatin-based chemotherapy with bevacizumab. A doublet with irinotecan combined with aflibercept was administered until progression of disease. The majority of patients received a greater number of aflibercept cycles than the median reported in the VELOUR study (12 vs. 7 cycles), with manageable and reversible toxicity. The most frequent adverse events observed were diarrhoea, neutropenia, fatigue, proteinuria and hypertension. Most cases obtained a progression-free survival greater than the median reported in the VELOUR study (11 vs. 6.9 months) and, in a subgroup of patients previously treated with bevacizumab, and a median survival time of ~47 months was reached from the initial treatment of the disease. The present study contrasts the efficacy and safety results obtained from the pivotal VELOUR trial, and confirms that aflibercept, used in routine clinical practice outside of the clinical trial environment, is active and well-tolerated following bevacizumab treatment.
Descripción : Journal Article;
URI: http://hdl.handle.net/10668/2623
Versión del editor : https://www.spandidos-publications.com/ol/12/5/3127
DOI: 10.3892/ol.2016.5068
ISSN : 1792-1074 (Online)
1792-1074 (Print)
Appears in Collections:01- Artículos - APES Costa del Sol
01- Artículos - Complejo Hospitalario Universitario de Granada

Files in This Item:
File Description SizeFormat 
Alcaide_EfficacyAndSafetyOfAflibercept.pdfArtículo publicado1,04 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons